원문 보기
The market is trembling. Headlines scream fear. Retail investors are selling in panic. But in the shadows, Cathie Wood, the boldest visionary on Wall Street, is doing the exact opposite. She's not hiding. She's aggressively loading up billions into the three revolutionary stocks that could ignite the next decade of explosive wealth creation.
These aren't ordinary bets. This is the unstoppable convergence of AI-powered medicine, the tokenized digital dollar, and actual gene editing cures. Technologies that will transform healthcare, money, and human biology forever. While others chase safe, boring returns, Cathie sees the once-in-a-generation inflection point unfolding right before our eyes.
She's buying the dips with conviction, adding hundreds of thousands of shares in recent weeks, including massive purchases when others fled. If you're tired of missing the biggest wealth transfers in history, if you want to align with the investor who turned early bets on Tesla, CRISPR, and Coinbase into legendary gains, then stay locked in.
Because these three stocks could deliver life-changing returns, and the window to position yourself is closing fast. Let's break down exactly why Cathie is all in, starting with the AI revolution that's about to personalize medicine like never before. Tempus AI TM, the AI brainpower revolutionizing precision medicine.
Cathie Wood has been relentlessly adding to Tempus AI throughout 2026, even during dips. As of late April, TM ranks as a top five holding in her flagship ARK Innovation ETF ARKK, with significant weight in ARKG as well. ARK has increased its stake multiple times, including big buys in March when the stock pulled back, signaling unbreakable conviction.
What? Tempus is building the world's largest multi-modal data set for oncology and beyond. Over 40 million clinical records and hundreds of petabytes of data, powered by AI to deliver personalized treatments at scale. Q4 FY 2025 results, reported February 2026, the company crushed it with $367.2 million in revenue, an explosive 83% year-over-year jump, including 33.5% organic growth.
Diagnostics revenue alone surged 121.6% to $266.9 million, driven by strong oncology and hereditary testing volume. Minimal residual disease MRD testing jumped 56% quarter-over-quarter. They hit their first positive adjusted EBITDA of $12.89 million. The full-year trajectory was strong, with over $1.1 billion in total remaining contract value, an impressive 126% net revenue retention.
For 2026, management guided $1.59 billion in revenue, about 25% growth, and roughly $65 million in adjusted EBITDA. Cathie sees the network effects compounding, AI advantages accelerating as more data flows in. Recent partnerships and biomarker discoveries only strengthen the moat. This is healthcare's AI moment.
While the stock has seen volatility, Cathie's repeated buying on weakness screams, "This is the future, and we're early." Circle Internet Group CRCL, the stablecoin king powering the future of money. Next up, Circle CRCL, the company behind USDC, one of the most trusted stablecoins on the planet. Cathie has been actively trading around this name in 2026, trimming at peaks, but aggressively buying dips, including a massive $16.3 million purchase in March when the stock crashed nearly 20% on regulatory noise.
As of April 2026, CRCL remains a solid holding across ARKK, ARKW, and ARKF, reflecting her belief in tokenized assets and digital dollar infrastructure as a core big idea for the year. Circle's IPO in mid-2025 was a blockbuster, and despite short-term volatility from proposed stablecoin yield rules or lawsuits, which ARK views as overreactions, the long-term thesis is rock-solid.
Partnerships like the push for USDC adoption in Africa, growing institutional use, and the broader crypto/fintech ecosystem play right into Cathie's vision of decentralized yet regulated finance. When the market panicked, Cathie saw opportunity. That's her signature move, turning fear into asymmetric upside.
If digital money goes mainstream, and she believes it will, Circle is positioned at the center. CRISPR Therapeutics CRSP, gene editing breakthrough era. Rounding out the trio, CRISPR Therapeutics CRSP, currently one of Cathie Wood's largest holdings, sitting at around 6.4% in ARKK as of April 2026, making it a top two or top three position in her flagship fund.
ARK has consistently added shares in 2026, including significant increases in Q4 2025, plus 7.5%, roughly 735k shares, and multiple dip-buying episodes in early 2026. Even after stock weakness or dilution news, Cathie keeps buying. A clear sign she views gene editing as still in its earliest innings.
Q4 FY 2025 results, reported February 2026, CRSP. Their groundbreaking CRISPR-based therapy for sickle cell disease and beta thalassemia, partnered with Vertex, generated $54 million in Q4 revenue and $116 million for the full year. 64 patients received infusions in 2025, with 147 initiating treatment.
Numbers that are growing, but represent just a fraction of the addressable market, tens of thousands of patients globally. The company reported a net loss, typical for a high-R&D biotech, but boasts a strong cash position of nearly $2 billion, providing runway for pipeline advancement in oncology, autoimmune, diabetes, and more.
Cathie sees this as transformative. Actual cures for genetic diseases. With regulatory tailwinds, expanding approvals, and manufacturing scale-up, the revenue ramp could be explosive in the coming years. ARK's Big Ideas report highlights CRISPR and related genomic plays as central to AI-native biology and multi-omics breakthroughs.
This isn't hype, it's science turning into medicine that changes lives and creates enormous shareholder value. Cathie Wood isn't waiting for permission. She's positioning ARK Invest for the explosive growth in AI healthcare, digital finance, and gene editing right now in 2026. Tempus AI is [clears throat] scaling precision medicine.
Circle is building the rails for the tokenized economy. CRISPR is delivering real cures. These are high-risk, high-reward names, volatile in the short term, but potentially life-altering over the next 5 to 10 years. What do you think? Is Cathie right to go all in on these three? Drop your thoughts in the comments.
Hit like if you're bullish on innovation, and subscribe for more deep dives into the stocks shaping our future. The revolution is happening. Don't watch from the sidelines. Get informed, stay ahead. I'll see you in the next video. Let's build wealth through disruptive innovation together.
Comments 0